Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
120,494,078
-
Total 13F shares
-
860,232
-
Share change
-
+23,736
-
Total reported value
-
$1,118,330
-
Price per share
-
$1.30
-
Number of holders
-
11
-
Value change
-
+$30,199
-
Number of buys
-
5
-
Number of sells
-
4
Institutional Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) as of Q3 2024
As of 30 Sep 2024,
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
860,232 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, BLAIR WILLIAM & CO/IL, GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, STATE STREET CORP, UBS Group AG, Tower Research Capital LLC (TRC), MORGAN STANLEY, and WELLS FARGO & COMPANY/MN.
This page lists
11
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.